Ciprodex

ApprovedSmall molecule

PPar Pharmaceutical, Inc.

Ciprodex is one of 22 small molecule programs targeting Otitis Externa. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Otitis ExternaActive, not recruiting

Suppurative Otitis MediaActive, not recruiting

Otitis MediaActive, not recruiting

Otitis ExternaPhase 3

Active, not recruiting

Suppurative Otitis MediaApproved

Active, not recruiting

Otitis MediaPhase 3

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Otitis Media

#DrugCompanyPhaseTrials

Cipro

Bayer

Approved

1 2

Keflex

Biaxin

Levaquin

Decadron

AAspen Global Incorporated

Approved

—6

Amoxil

GGlobal Antibiotics Research and Development Partnership

Ketek

1 8

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

1 10

Ciprodex

PPar Pharmaceutical, Inc.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Otitis Externa3 trials

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

Completed·EExela Pharma Sciences, LLC.·Phase 3·NCT02216071·499 enrolled

FST-201 in the Treatment of Acute Otitis Externa

Completed· Takeda logo

Takeda·Phase 3·NCT00961675·70 enrolled

A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa

Terminated·PPar Pharmaceutical, Inc.·Phase 3·NCT01910155·455 enrolled

Outcome1 trial

Otiprio Versus Ciprodex Tympanostomy Tube Outcomes

Withdrawn·—·Phase 4·NCT03347461

Suppurative Otitis Media1 trial

N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media

Withdrawn·SSt. Paul's Hospital, Canada·Phase 4·NCT00956748

Otitis media1 trial

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Terminated·PPar Pharmaceutical, Inc.·Phase 3·NCT01994642·203 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Ciprodex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ciprodex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ciprodex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Par Pharmaceutical, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: PPar Pharmaceutical, Inc.

Ciprodex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Otitis Externa3 trials

Outcome1 trial

Suppurative Otitis Media1 trial

Otitis media1 trial

References

Drug Info

Quick Facts

Related News